Lenzilumab
- CAS No.
- 1229575-09-0
- Chemical Name:
- Lenzilumab
- Synonyms
- Lenzilumab;Lenzilumab (anti-GM-CSF);Research Grade Lenzilumab;Research Grade Lenzilumab(DHC06703)
- CBNumber:
- CB18080915
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | IE4X6497XK |
| NCI Drug Dictionary | lenzilumab |
Lenzilumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612967 | Lenzilumab 99.64% | 1229575-09-0 | 1mg | $303 | 2026-06-04 | Buy |
| ChemScene | CS-0612967 | Lenzilumab 99.64% | 1229575-09-0 | 5mg | $758 | 2026-06-04 | Buy |
| ChemScene | CS-0612967 | Lenzilumab 99.64% | 1229575-09-0 | 10mg | $1213 | 2026-06-04 | Buy |
| aablocks | AA029IZE | Lenzilumab ≥95%(SDS-PAGE&SEC-HPLC) | 1229575-09-0 | 1mg | $480 | 2026-06-02 | Buy |
| aablocks | AA029IZE | Lenzilumab ≥95%(SDS-PAGE&SEC-HPLC) | 1229575-09-0 | 5mg | $1200 | 2026-06-02 | Buy |
Lenzilumab Chemical Properties, Uses, Production
Uses
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].
in vivo
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].
| Animal Model: | NSG mice with CART19 cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; daily; 10 days |
| Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
References
[1] Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709. DOI:10.1182/blood-2018-10-881722
[2] Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. DOI:10.1016/j.mayocp.2020.08.038
Lenzilumab Preparation Products And Raw materials
Raw materials
Preparation Products
Lenzilumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
View Latest Price from Lenzilumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Lenzilumab
1229575-09-0
|
$183.00-742.00 | 95.00% | 10g | TargetMol Chemicals Inc. |
-
- Lenzilumab
1229575-09-0
- $183.00-742.00
- 95.00%
- TargetMol Chemicals Inc.
